{"created":"2023-05-15T14:59:39.704001+00:00","id":80951,"links":{},"metadata":{"_buckets":{"deposit":"5ad0cc4a-b31b-407d-ad47-ff4ef8ec103f"},"_deposit":{"created_by":1,"id":"80951","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"80951"},"status":"published"},"_oai":{"id":"oai:repo.qst.go.jp:00080951","sets":["10:29"]},"author_link":["900478","900476","900479","900477"],"item_10005_date_7":{"attribute_name":"発表年月日","attribute_value_mlt":[{"subitem_date_issued_datetime":"2020-11-12","subitem_date_issued_type":"Issued"}]},"item_10005_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Liver metastasis (LM) is often found in patients with gastric cancer (GC) and the prognosis is miserable. HER2 is overexpressed in 7-34% of LMGC. Alpha-radioimmunotherapy (α-RIT) is expected to be a promising therapeutic option for metastasis with the combination of cancer specific drug delivery of antibody and high cell cytotoxicity of α-particle. Astatine 211 (At-211) is an attractive α-particle emitter with appropriate half-life and producible with cyclotron.\nWe have investigated the therapeutic efficacy and toxicity of α-RIT with [At-211]-trastuzumab against LMGC using preclinical mice model. A single injection of [At-211]-trastuzumab effectively eradicated LMGC without recurrence in 6/8 mice and significantly prolonged the survival compared to control. There was no severe toxicity observed as long as we monitored.","subitem_description_type":"Abstract"}]},"item_10005_description_6":{"attribute_name":"会議概要（会議名, 開催地, 会期, 主催者等）","attribute_value_mlt":[{"subitem_description":"第60回日本核医学会学術総会","subitem_description_type":"Other"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"李, 惠子"}],"nameIdentifiers":[{"nameIdentifier":"900476","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"長谷川, 純崇"}],"nameIdentifiers":[{"nameIdentifier":"900477","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Li, Huizi","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"900478","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Hasegawa, Sumitaka","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"900479","nameIdentifierScheme":"WEKO"}]}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"conference object","resourceuri":"http://purl.org/coar/resource_type/c_c94f"}]},"item_title":"胃がん肝転移に対するα線放射免疫療法の⾮臨床研究","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"胃がん肝転移に対するα線放射免疫療法の⾮臨床研究"}]},"item_type_id":"10005","owner":"1","path":["29"],"pubdate":{"attribute_name":"公開日","attribute_value":"2020-11-13"},"publish_date":"2020-11-13","publish_status":"0","recid":"80951","relation_version_is_last":true,"title":["胃がん肝転移に対するα線放射免疫療法の⾮臨床研究"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-15T21:18:20.654047+00:00"}